MDS (myelodysplastic syndrome) transfection leukocyte line with capacity of stable expression of GFP (green fluorescent protein)

Abstract

The invention belongs to the field of microbial and animal cell lines and provides an MDS (myelodysplastic syndrome) transfection leukocyte line with capacity of stable expression of GFP (green fluorescent protein) as well as establishment method and an application of the MDS transfection leukocyte line. A human MDS transfection leukocyte line SKM-1 is taken as maternal cells and is transfected through lentiviruses carrying GFP genes, GFP-positive single cells are obtained with a limiting dilution method and cloned, cells after amplified culture are screened in a mouse body in a subcutaneous injection manner, tumor masses are separated after tumorigenesis and cultured continuously, and the MDS transfection leukocyte line SKM-1 / GFP with stable expression of GFP is obtained. The morphology, growth characteristics and the growth curve of the cell line have no difference with those of the maternal cells, and the cell line can express GFP stably, has tumorigenicity, can be further applied to establishment of a murine animal model and provides a platform for MDS, minimal residual disease and other preclinical study.

Description

technical field [0001] The invention belongs to the fields of biotechnology and microbial animal cell lines, and relates to a myelodysplastic syndrome-transformed leukocyte strain, in particular to a myelodysplastic syndrome-transformed leukocyte strain stably expressing green fluorescent protein and its preparation method and application. Background technique [0002] The prior art discloses that myelodysplastic syndrome (myelodysplastic syndeome, MDS) is a group of diseases of abnormal proliferation of clonal cells, characterized by ineffective hematopoiesis, pathological hematopoiesis and high risk of transformation to acute myeloid leukemia (AML), among which about 20%-30% of MDS patients progress to AML. According to reports, in the United States, MDS is the most common tumor of myeloid origin, and the incidence rate of men is higher than that of women, with an average of every 10 5 In every American, 3-4 people suffer from MDS; with the increase of age, the incidence ...

AI Technical Summary

Problems solved by technology

Compared with denovo AML, patients with MDS-transformed AML (sAML) are older and more difficult to treat, and often cannot be treated with allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and intensive chemotherapy, and their prognosis is poor; Research also shows that with the development of demethylation drugs such as decitabine and azacitidine, breakthroughs have been made in the treatment of MDS, but these drugs have limited therapeutic effects on high-risk MDS and sAML

Due to the lack of effective treatment methods in clinical practice, it is difficult to remove leukemia cells in the body, which ultimately threatens the lives of patients; however, there is currently a lack of effective and reliable in vivo and in vitro research platforms at home and abroad, which seriously restricts the basic and preclinical research of MDS

Images